Literature DB >> 35186370

Willingness of the General Public to Receive A COVID-19 Vaccine Booster - China, April-May 2021.

Xiaoxiao Wang1, Leyuan Liu2, Minyue Pei1, Xiaoguang Li2, Nan Li1.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: A coronavirus disease 2019 (COVID-19) vaccine booster is planned for administration to eligible individuals. Understanding the factors that influence attitudes towards the booster shot will help to identify groups that will most readily accept a booster dose. WHAT IS ADDED BY THIS REPORT?: Of the individuals polled, 75.2% reported they would receive a booster shot. Sociodemographic characteristics influencing booster vaccine acceptance included age, gender, occupation, and education. Moreover, those who had been vaccinated against influenza, who believed herd immunity would be effective against severe acute respiratory syndrome coronavirus 2, and who reported reduced anxiety after vaccination were more likely to accept a booster dose. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: A booster shot of the COVID-19 vaccine could be widely accepted. Communicating about the effectiveness of the COVID-19 vaccine and the impact of infection on people's health could help increase public willingness to get a booster dose. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022.

Entities:  

Keywords:  COVID-19; booster; vaccine

Year:  2022        PMID: 35186370      PMCID: PMC8837444          DOI: 10.46234/ccdcw2022.013

Source DB:  PubMed          Journal:  China CDC Wkly        ISSN: 2096-7071


On October 11, 2021, the strategic advisory group of experts (SAGE) of the World Health Organization (WHO) recommended that an additional dose of coronavirus disease 2019 (COVID-19) vaccine should be offered to moderately and severely immunocompromised people and to those aged 60 and over who were previously immunized with Sinovac or Sinopharm inactivated vaccines (1). The National Health Commission of the People’s Republic of China (NHC) and the United States Centers for Disease Control Advisory Committee on Immunization Practices (ACIP) are planning a COVID-19 vaccine booster so that vaccinated people can maintain protection over the coming months (2-3). Numerous studies have shown that vaccination willingness is influenced by a variety of factors and that it changes over time (4-5). It is necessary to understand the public’s willingness to receive a COVID-19 vaccine booster. Identifying factors that influence booster vaccine acceptance will aid in determining who is most likely to accept a booster dose. Online questionnaires were completed by 2,047 vaccinated Chinese adults in April and May 2021. Respondents’ sociodemographic characteristics, attitudes towards vaccination, and attitudes towards a COVID-19 vaccine booster were collected. All data were analyzed using R statistical software (version 4.0.3, R Core Team, Vienna, Austria). Logistic regression models were built to identify factors associated with respondents’ acceptance of a COVID-19 vaccine booster. The odds ratio (OR) and its corresponding 95% confidence interval (CI) were calculated. Of the respondents, 75.2% reported they planned to receive a booster shot. Respondents who expressed significantly higher acceptance of a booster dose tended to be aged 25–54 years old, male, non-healthcare workers, and less educated. Moreover, those who had been vaccinated against influenza (OR=1.26, 95% CI: 1.01–1.57), who believed herd immunity would be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (OR=3.58, 95% CI: 2.69–4.77), or who reported reduced anxiety after vaccination (OR=1.27, 95% CI: 1.02–1.59) were more likely to report planning to receive a booster dose. Based on these results, it seems that a booster shot of the COVID-19 vaccine could be widely accepted in China. Communicating to the public the effectiveness of COVID-19 vaccines and the impact of COVID-19 infection on one’s health could increase individuals’ willingness to receive a booster dose. In April and May 2021, an online questionnaire was disseminated via WeChat, a Chinese multipurpose social media app. Using WeChat moments, which spread questionnaires by snowballing, 1,656 respondents were recruited. To reduce the risk of bias due to starting with a single sample source, 403 additional respondents were recruited via the Tencent questionnaire sample database. This database contains over 1 million people with verified personal information, and we used the recruitment service to recruit subjects aged ≥18. Incomplete questionnaires were excluded. The final sample consisted of 2,047 respondents. Respondents’ sociodemographic characteristics, flu vaccination history, attitudes towards herd immunity, anxiety levels after initial vaccination, acceptance of a booster shot, and antibody tests were collected. The study was approved by Peking University Third Hospital Medical Science Research Ethics Committee (No. 2021-184-01). The age- and gender-standardized acceptance rate of a COVID-19 vaccine booster was calculated using the 2010 population census of China as the reference (6). Logistic regression models were built to identify factors influencing COVID-19 vaccine booster acceptance (event: receiving COVID-19 vaccine booster when available). All data were analyzed using R statistical software. A P-value <0.05 was considered statistically significant. Of the 2,047 vaccinated respondents (Table 1), 1,540 (75.2%) reported that they planned to receive a COVID-19 vaccine booster shot when it was available. The age- and gender-standardized acceptance rate was 75.8% (Table 2). In addition, 1,257 (81.6% of those who planned to receive the booster shot) reported that they would receive antibody tests, which could help to determine the effectiveness of the booster dose.
Table 1

Characteristics of the study population.

Characteristics WeChat sample (n=1,644) Tencent sample (n=403)
Note: All data are described in term of “Number (%) of participants”. Abbreviation: CNY=China Yuan.
Age group, years
18–24184 (11.3)14 (3.5)
25–34614 (37.6)18 (4.5)
35–44451 (27.6)43 (10.7)
45–54254 (15.5)245 (60.8)
55–6491 (5.6)68 (16.9)
≥6541 (2.5)15 (3.7)
Gender
Male613 (37.3)164 (40.7)
Female1,031 (62.7)239 (59.3)
Non-healthcare staff
Yes973 (59.2)398 (98.8)
No671 (40.8)5 (1.2)
Education
Junior high school and below105 (6.4)135 (33.5)
Senior high school78 (4.7)216 (53.6)
Associate or bachelor809 (49.2)49 (12.2)
Master and above652 (39.7)3 (0.7)
Income (CNY per month)
0–2,000201 (12.2)106 (26.3)
2,000–5,000300 (18.3)221 (54.8)
5,000–10,000459 (27.9)66 (16.4)
10,000 and above684 (41.6)10 (2.5)
Area type
Rural1,498 (91.6)285 (70.9)
Urban138 (8.4)117 (29.1)
Flu vaccination history
Yes680 (41.4)189 (46.9)
No/unsure964 (58.6)214 (53.1)
Whether herd immunity works
Yes1,423 (86.6)382 (94.8)
No/unsure221 (13.4)21 (5.2)
Whether vaccination help reduce anxiety
Yes1,098 (66.8)268 (66.5)
No546 (33.2)135 (33.5)
Table 2

The process of calculating age- and gender- standardized acceptance rate of a COVID-19 vaccine booster.

Age (year) Gender Observed acceptance rates (%)Population according to census 2016 Expected number
Note: The age- and gender- standardized acceptance rate of a COVID-19 vaccine booster equals 75.8%. Abbreviation: COVID-19=coronavirus disease 2019.
18–24Female71.083,878,76259,553,921
Male77.085,832,49666,091,022
25–34Female69.097,793,19567,477,305
Male76.4100,358,86076,674,169
35–44Female73.1118,780,14186,828,283
Male80.5123,999,78299,819,825
45–54Female78.390,208,07270,632,920
Male86.294,139,65281,148,380
55–64Female67.769,062,39246,755,239
Male81.870,917,36458,010,404
≥65Female60.649,507,02930,001,260
Male82.648,430,78340,003,827
Total75.21,032,908,528782,996,554
COVID-19 vaccine booster acceptance rate was highest among adults aged 45–54 years (81.2%) and lowest among adults aged ≥65 years (69.6%). Male respondents were more likely than female respondents to accept a COVID-19 vaccine booster (80.2%vs. 72.2%), and those who were not healthcare workers were more likely to accept a booster dose than healthcare workers (79.3% vs.67.0%). Respondents who held a bachelor’s degree or below were more likely to accept a booster dose (68.9%, 74.5%, 83.3%, vs. 85.4%). Vaccine booster acceptance was slightly higher among respondents who earned <5,000 CNY per month (77.7% vs. 73.6%). Respondents who lived in rural areas were more likely to accept a booster dose (83.1% vs. 74.1%). Moreover, those who had been vaccinated against influenza (77.7% vs. 73.4% who had not been), who believed herd immunity would be effective against SARS-CoV-2 (78.9% vs. 47.5% who did not believe this), and who reported reduced anxiety after vaccination (77.0% vs. 71.7% who did not report this) were more likely to accept a booster dose. The multiple logistic regression model identified the people most likely to get the booster dose as soon as it was available (Table 3). Those who expressed significantly higher acceptance of a booster dose included respondents who were: 25–34 years old (OR=2.06, 95% CI: 1.09–3.91); 35–44 years old (OR=2.24, 95% CI: 1.18–4.28); 45–54 years old (OR=2.07, 95% CI: 1.09–3.94); male (OR=1.33, 95% CI: 1.05–1.67); and non-healthcare workers (OR=1.50, 95% CI: 1.17–1.92). Booster shot acceptance was also higher among those who had: a junior high school level of education or below (OR=2.64, 95% CI: 1.50–4.62); a high school level of education (OR=2.12, 95% CI: 1.34–3.35); and who had been vaccinated against influenza (OR=1.26, 95% CI: 1.01–1.57). Finally, those who believed herd immunity would be effective against SARS-CoV-2 or who reported reduced anxiety after vaccination were more likely to accept a booster dose (OR=3.58, 95% CI: 2.69–4.77 and OR=1.27, 95% CI: 1.02–1.59, respectively).
Table 3

Influencing factors on COVID-19 vaccine booster preference.

Characteristics COVID-19 vaccine booster preference Univariate analysis Multivariate analysis
No (percentage %) Yes (percentage %) Crude OR (95% CI) P Adjusted OR (95% CI) P
Abbreviations: COVID-19=coronavirus disease 2019; OR=odds ratio; CI=confidence interval; CNY=China Yuan; Ref.=reference.
Age group, years
18–2453 (26.8)145 (73.2)1.19 (0.62, 2.29)0.5961.99 (0.97, 4.10)0.062
25–34178 (28.2)454 (71.8)1.11 (0.61, 2.02)0.7272.06 (1.09, 3.91)0.026
35–44119 (24.1)375 (75.9)1.37 (0.75, 2.52)0.3042.24 (1.18, 4.28)0.014
45–5494 (18.8)405 (81.2)1.88 (1.02, 3.46)0.0442.07 (1.09, 3.94)0.026
55–6442 (26.4)117 (73.6)1.21 (0.62, 2.37)0.5701.14 (0.56, 2.30)0.719
≥6517 (30.4)39 (69.6)Ref.Ref.
Gender<0.0010.016
Male154 (19.8)623 (80.2)1.56 (1.26, 1.93)1.33 (1.05, 1.67)
Female353 (27.8)917 (72.2)Ref.Ref.
Non-healthcare staff<0.0010.002
Yes284 (20.7)1,087 (79.3)1.88 (1.53, 2.32)1.50 (1.17, 1.92)
No223 (33.0)453 (67.0)Ref.Ref.
Education
Junior high school and below35 (14.6)205 (85.4)2.65 (1.79, 3.93)<0.0012.64 (1.50, 4.62)0.001
Senior high school49 (16.7)245 (83.3)2.26 (1.60, 3.20)<0.0012.12 (1.34, 3.35)0.001
Associate or bachelor219 (25.5)639 (74.5)1.32 (1.05, 1.65)0.0161.26 (0.98,1.63)0.070
Master and above204 (31.1)451 (68.9)Ref.Ref.
Income (CNY per month)
0–2,00071 (23.1)236 (76.9)1.22 (0.89, 1.67)0.2200.64 (0.40, 1.01)0.054
2,000–5,000114 (21.9)407 (78.1)1.31 (1.00, 1.71)0.0490.83 (0.59, 1.16)0.269
5,000–10,000136 (25.9)389 (74.1)1.05 (0.81, 1.36)0.7250.86 (0.65, 1.15)0.309
10,000 and above186 (26.8)508 (73.2)Ref.Ref.
Residence0.0020.553
Rural43 (16.9)212 (83.1)1.72 (1.22, 2.43)1.14 (0.74, 1.76)
Urban461 (25.9)1,322 (74.1)Ref.Ref.
Flu vaccination history0.0280.039
Yes194 (22.3)675 (77.7)1.26 (1.03, 1.55)1.26 (1.01, 1.57)
No/unsure313 (26.6)865 (73.4)Ref.Ref.
Whether herd immunity works<0.001<0.001
Yes380 (21.1)1,425 (78.9)4.14 (3.14, 5.46)3.58 (2.69, 4.77)
No/unsure127 (52.5)115 (47.5)Ref.Ref.
Whether vaccination help reduce anxiety0.0080.035
Yes314 (23.0)1,052 (77.0)1.33 (1.08, 1.63)1.27 (1.02, 1.59)
No193 (28.3)488 (71.7)Ref.Ref.

DISCUSSION

This survey demonstrated that most of the vaccinated respondents (75.2%) would accept a COVID-19 vaccine booster shot when it became available. Although data on the efficacy and safety of the booster shot are still lacking, booster shots have a higher level of acceptance now than earlier doses of the vaccines did (4). Multiple studies have shown that vaccine acceptance changes over time, and the proportion of people who accept a vaccine may rise as the pandemic continues to fluctuate and the safety of vaccines is properly reported (4-5). Sociodemographic characteristics were important factors affecting the acceptability of the COVID-19 vaccine booster. Respondents who were aged 25–54 years old, male, non-healthcare workers, and less educated expressed significantly higher acceptance of the booster dose. According to WHO recommendations, people aged 60 or older who received inactivated vaccines should receive booster shots. The relatively low acceptance among people over 60 is therefore of great concern. Moreover, those who had been vaccinated against influenza (OR=1.26, 95% CI: 1.01–1.57), who believed herd immunity would be effective against SARS-COV-2 (OR=3.58, 95% CI: 2.69–4.77) or who reported reduced anxiety after vaccination (OR=1.27, 95% CI: 1.02–1.59) were more likely to accept a booster dose. These results suggest that strong confidence in the vaccines would lead to more people getting vaccinated, which is consistent with previous studies (7-8). Therefore, efforts focused on clearly communicating to the public the effectiveness and safety of the COVID-19 booster vaccination and the risk of getting sick and dying from COVID-19 could help increase public willingness to get vaccinated. This is the first study to address public acceptance of a booster shot of COVID-19 vaccines, and we find that they are likely to be widely accepted. This survey identifies priority groups to target for COVID-19 vaccine booster shots, which is of crucial importance in public health policy implementation (9). This study was subject to some limitations. First is that convenience sampling was used, which may affect the representativeness of the individuals sampled compared to the population as a whole. The epidemic was relatively stable when the survey was conducted and therefore not causing a great amount of panic among members of the public, which suggests that this sample provided some insight to public willingness to get a booster dose. Second, acceptance of a COVID-19 vaccine booster could also be influenced by information spread in the media and on social networks, including the local number of daily confirmed cases, the capacity of healthcare services, and relevant policies in different areas. However, we are unable to consider these issues in this study due to unavailability of the data. Further investigation is therefore needed in the future.

Conflicts of interest

No conflicts of interest declared.
  4 in total

1.  Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors.

Authors:  Qiang Wang; Liuqing Yang; Hui Jin; Leesa Lin
Journal:  Prev Med       Date:  2021-06-22       Impact factor: 4.018

2.  Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity.

Authors:  Shasha Han; Jun Cai; Juan Yang; Juanjuan Zhang; Qianhui Wu; Wen Zheng; Huilin Shi; Marco Ajelli; Xiao-Hua Zhou; Hongjie Yu
Journal:  Nat Commun       Date:  2021-08-03       Impact factor: 14.919

  4 in total
  10 in total

1.  Changes of COVID-19 Knowledge, Attitudes, Practices and Vaccination Willingness Among Residents in Jinan, China.

Authors:  Ning Jiang; Cheng Yang; Wenjing Yu; Liyan Luo; Xin Tan; Liping Yang
Journal:  Front Public Health       Date:  2022-05-20

2.  Health Beliefs and Socioeconomic Determinants of COVID-19 Booster Vaccine Acceptance: An Indonesian Cross-Sectional Study.

Authors:  Gede Benny Setia Wirawan; Ngakan Putu Anom Harjana; Nur Wulan Nugrahani; Pande Putu Januraga
Journal:  Vaccines (Basel)       Date:  2022-05-05

3.  COVID-19 Vaccines and Public Anxiety: Antibody Tests May Be Widely Accepted.

Authors:  Leyuan Liu; Xiaoxiao Wang; Xiaoguang Li; Nan Li
Journal:  Front Public Health       Date:  2022-05-06

4.  Willingness and Perceptions Regarding COVID-19 Vaccine Booster Dose in Pakistani Vaccinated Population: A Cross-Sectional Survey.

Authors:  Abdul Moeed; Hala Najeeb; Arisha Saleem; Muhammad Sohaib Asghar; Hania Mansoor Rafi; Abdullah Khan Khattak; Zoha Bilal; Binyam Tariku Seboka
Journal:  Front Public Health       Date:  2022-06-30

5.  COVID-19 Vaccine Booster Hesitancy (VBH) and Its Drivers in Algeria: National Cross-Sectional Survey-Based Study.

Authors:  Mohamed Lounis; Djihad Bencherit; Mohammed Amir Rais; Abanoub Riad
Journal:  Vaccines (Basel)       Date:  2022-04-15

6.  Predictors of Willingness of the General Public to Receive a Second COVID-19 Booster Dose or a New COVID-19 Vaccine: A Cross-Sectional Study in Greece.

Authors:  Petros Galanis; Irene Vraka; Aglaia Katsiroumpa; Olga Siskou; Olympia Konstantakopoulou; Theodoros Katsoulas; Theodoros Mariolis-Sapsakos; Daphne Kaitelidou
Journal:  Vaccines (Basel)       Date:  2022-06-30

Review 7.  First COVID-19 Booster Dose in the General Population: A Systematic Review and Meta-Analysis of Willingness and Its Predictors.

Authors:  Petros Galanis; Irene Vraka; Aglaia Katsiroumpa; Olga Siskou; Olympia Konstantakopoulou; Theodoros Katsoulas; Theodoros Mariolis-Sapsakos; Daphne Kaitelidou
Journal:  Vaccines (Basel)       Date:  2022-07-08

8.  Behavioral Intention and Its Predictors toward COVID-19 Booster Vaccination among Chinese Parents: Applying Two Behavioral Theories.

Authors:  Meng Zhou; Li Liu; Shu-Yan Gu; Xue-Qing Peng; Chi Zhang; Qi-Feng Wu; Xin-Peng Xu; Hua You
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

9.  Study of the Side Effects of Pfizer and Oxford COVID-19 Vaccines in the Eastern Province of Saudi Arabia.

Authors:  Maha Farhat; Rabab Al-Ibrahim; Abrar Almohammedali; Roaa Aljishi; Baneen Alalwan
Journal:  Int J Gen Med       Date:  2022-09-28

10.  Willingness to Take the Booster Vaccine in a Nationally Representative Sample of Danes.

Authors:  Frederik Juhl Jørgensen; Louise Halberg Nielsen; Michael Bang Petersen
Journal:  Vaccines (Basel)       Date:  2022-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.